MX2022001210A - Moléculas de complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. - Google Patents
Moléculas de complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.Info
- Publication number
- MX2022001210A MX2022001210A MX2022001210A MX2022001210A MX2022001210A MX 2022001210 A MX2022001210 A MX 2022001210A MX 2022001210 A MX2022001210 A MX 2022001210A MX 2022001210 A MX2022001210 A MX 2022001210A MX 2022001210 A MX2022001210 A MX 2022001210A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- amino acid
- methods
- hla class
- class
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880501P | 2019-07-30 | 2019-07-30 | |
| US202063029114P | 2020-05-22 | 2020-05-22 | |
| PCT/IB2020/057173 WO2021019473A1 (en) | 2019-07-30 | 2020-07-29 | Mhc class ii molecules and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001210A true MX2022001210A (es) | 2022-05-03 |
Family
ID=74228599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001210A MX2022001210A (es) | 2019-07-30 | 2020-07-29 | Moléculas de complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12590139B2 (enExample) |
| EP (1) | EP4004034A4 (enExample) |
| JP (1) | JP7811540B2 (enExample) |
| KR (1) | KR20220052943A (enExample) |
| CN (1) | CN114450302A (enExample) |
| AU (1) | AU2020322246A1 (enExample) |
| BR (1) | BR112022001710A2 (enExample) |
| CA (1) | CA3146292A1 (enExample) |
| IL (1) | IL290223A (enExample) |
| MX (1) | MX2022001210A (enExample) |
| TW (1) | TW202116797A (enExample) |
| WO (1) | WO2021019473A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113795583B (zh) | 2019-03-04 | 2026-03-27 | 大学健康网络 | T细胞受体及其使用方法 |
| WO2021019475A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| CN118662607A (zh) * | 2023-03-15 | 2024-09-20 | 中国科学院上海巴斯德研究所 | 抑制过激炎性反应的蛋白及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0958834B1 (en) | 1996-11-13 | 2007-07-04 | Meiji Dairies Corporation | Use of peptide-based immunotherapeutic agent |
| IL157073A0 (en) | 2001-01-24 | 2004-02-08 | Harvard College | Therapeutic peptides for demyelinating conditions |
| GB0107628D0 (en) | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| WO2003008450A1 (en) | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Tumor antigen |
| US20080070835A1 (en) * | 2003-11-05 | 2008-03-20 | International Institute Of Cancer Immunology, Inc | Hla-Dr-Binding Antigen Peptide Derived From Wt1 |
| CN101001868A (zh) | 2004-06-17 | 2007-07-18 | 曼康公司 | 表位类似物 |
| US20060228758A1 (en) * | 2004-09-13 | 2006-10-12 | Xencor, Inc. | Analysis of MHC-peptide binding interactions |
| WO2006031883A2 (en) | 2004-09-13 | 2006-03-23 | Xencor, Inc. | Analysis of mhc-peptide binding interactions |
| US20100099090A1 (en) | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2016135363A1 (es) | 2015-02-23 | 2016-09-01 | Servicio Andaluz De Salud | Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c |
| EP3337822A1 (en) | 2015-08-19 | 2018-06-27 | Rutgers, The State University of New Jersey | Novel methods of generating antibodies |
| CA3022227A1 (en) | 2016-04-27 | 2017-11-02 | University Health Network (Uhn) | Peptide-hla complexes and methods of producing same |
| CN111712254A (zh) | 2017-12-23 | 2020-09-25 | 鲁比厄斯治疗法股份有限公司 | 人工抗原呈递细胞和使用方法 |
| WO2021019476A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Methods of identifying t cell receptors |
| WO2021019475A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| WO2021019474A1 (en) | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
-
2020
- 2020-07-29 WO PCT/IB2020/057173 patent/WO2021019473A1/en not_active Ceased
- 2020-07-29 MX MX2022001210A patent/MX2022001210A/es unknown
- 2020-07-29 CN CN202080067823.XA patent/CN114450302A/zh active Pending
- 2020-07-29 TW TW109125665A patent/TW202116797A/zh unknown
- 2020-07-29 EP EP20848105.1A patent/EP4004034A4/en active Pending
- 2020-07-29 BR BR112022001710A patent/BR112022001710A2/pt unknown
- 2020-07-29 AU AU2020322246A patent/AU2020322246A1/en active Pending
- 2020-07-29 US US17/631,821 patent/US12590139B2/en active Active
- 2020-07-29 JP JP2022506467A patent/JP7811540B2/ja active Active
- 2020-07-29 KR KR1020227006943A patent/KR20220052943A/ko active Pending
- 2020-07-29 CA CA3146292A patent/CA3146292A1/en active Pending
-
2022
- 2022-01-30 IL IL290223A patent/IL290223A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4004034A4 (en) | 2023-11-15 |
| EP4004034A1 (en) | 2022-06-01 |
| TW202116797A (zh) | 2021-05-01 |
| IL290223A (en) | 2022-03-01 |
| KR20220052943A (ko) | 2022-04-28 |
| AU2020322246A1 (en) | 2022-03-03 |
| CA3146292A1 (en) | 2021-02-04 |
| US12590139B2 (en) | 2026-03-31 |
| BR112022001710A2 (pt) | 2022-06-21 |
| US20220275051A1 (en) | 2022-09-01 |
| WO2021019473A1 (en) | 2021-02-04 |
| CN114450302A (zh) | 2022-05-06 |
| JP2022542447A (ja) | 2022-10-03 |
| JP7811540B2 (ja) | 2026-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| MX2013003884A (es) | Metodo para activar celulas auxiliares. | |
| CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
| PE20181923A1 (es) | Neoantigenos y metodos de su uso | |
| MX2022001211A (es) | Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. | |
| CL2023001860A1 (es) | Composiciones y métodos para reducir hla-a en una célula | |
| CR20230303A (es) | Composiciones y métodos para reducir el mhc de clase ii en una célula | |
| CL2018000124A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| MX2011011132A (es) | Peptido auxiliar del antigeno del cancer. | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| HRP20110240T1 (en) | Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
| CL2023001855A1 (es) | Composiciones y métodos para modificar genéticamente ciita en una célula | |
| AR081354A1 (es) | Metodos y reactivos par una transferencia genica eficaz y dirigida a monocitos y macrofagos | |
| MX2021005313A (es) | Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico. | |
| CL2023001735A1 (es) | Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas | |
| MX2015007745A (es) | Metodo para activar la celula t auxiliar. | |
| MX2022001204A (es) | Métodos de identificación de receptores de linfocitos t. | |
| MX2022001033A (es) | Aptámeros anti-cd3 para uso en direccionamiento y etiquetado de células. | |
| ATE544848T1 (de) | Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais) | |
| ECSP23024373A (es) | Composición para inmunoterapia | |
| MX2021010542A (es) | Receptores de linfocitos t y metodos de uso de estos. | |
| BR112016018826A8 (pt) | anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos |